|
CP-615,003 is a drug which acts as a subtype-selective partial agonist at GABAA receptors, and was developed by Pfizer as a potential anxiolytic, however poor blood–brain barrier penetration make it primarily useful as a research ligand. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「CP-615,003」の詳細全文を読む スポンサード リンク
|